NASDAQ:ONC BeOne Medicines Q2 2025 Earnings Results & Report $349.08 -1.32 (-0.38%) Closing price 04:00 PM EasternExtended Trading$349.30 +0.22 (+0.06%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. BeOne Medicines beat analyst expectations on both earnings and revenue in its Q2 2025 results, released August 6, 2025. The company reported EPS of $0.84 versus the $0.48 consensus estimate, while revenue of $1.32 billion topped the $1.24 billion estimate by $76.45 million. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2025Report DateAugust 6, 2025TimeBefore Market Opens BeOne Medicines EPS ResultsActual EPS$0.84Consensus EPS $0.48Beat/MissBeat by +$0.36One Year Ago EPSN/AEPS Beat Rate3 of last 5 quartersBeOne Medicines Revenue ResultsActual Revenue$1.32 billionExpected Revenue$1.24 billionBeat/MissBeat by +$76.45 millionYoY Revenue GrowthN/AConference Call ResourcesEarnings HistoryCompany Profile BeOne Medicines Q2 2025 Earnings FAQ Did BeOne Medicines beat earnings estimates for Q2 2025? BeOne Medicines (NASDAQ:ONC) reported earnings of $0.84 per share for Q2 2025, beating the consensus estimate of $0.48. The report was announced on Wednesday, August 6, 2025. What was BeOne Medicines' revenue for Q2 2025? BeOne Medicines reported revenue of $1.32 billion for Q2 2025, against a consensus estimate of $1.24 billion. BeOne Medicines Earnings HeadlinesBeOne Medicines (ONC) Surged on Strong Financial Performance and Upgraded GuidanceOctober 13 at 8:31 AM | insidermonkey.comBeOne Medicines (NASDAQ:ONC) Stock Gets Price Target Bump from Royal Bank Of CanadaOctober 10 at 3:18 AM | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.October 13 at 1:00 AM | Chaikin Analytics (Ad)Truist Financial Forecasts Strong Price Appreciation for BeOne Medicines (NASDAQ:ONC) StockOctober 9, 2026 | americanbankingnews.comBeOne Medicines AG (ONC)October 8, 2026 | finance.yahoo.comBeOne Medicines (NASDAQ:ONC) Stock Rating Lowered by Zacks ResearchOctober 7, 2026 | americanbankingnews.comSee More BeOne Medicines Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like BeOne Medicines? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BeOne Medicines and other key companies, straight to your email. Email Address About BeOne MedicinesBeOne Medicines (NASDAQ:ONC) Ltd. (NASDAQ: ONC) is a global oncology company focused on discovering, developing, manufacturing and commercializing medicines for people with cancer. The company operates across the research and development, clinical testing, regulatory and commercial stages of the biopharmaceutical industry, with an emphasis on treatments for blood cancers and solid tumors. Its marketed portfolio includes BRUKINSA (zanubrutinib), a Bruton’s tyrosine kinase inhibitor used to treat several B-cell malignancies, and TEVIMBRA (tislelizumab), an immunotherapy targeting the PD-1 pathway for certain cancers. BeOne also has a pipeline of investigational therapies designed to address additional hematologic and solid-tumor indications. The company was founded in 2010 as BeiGene and adopted the BeOne Medicines name as part of its evolution into a global oncology-focused business. It serves patients and healthcare providers in China, the United States, Europe and other international markets. John V. Oyler, the company’s founder, serves as chief executive officer.View BeOne Medicines ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Surgical Precision, Sustainable Returns: Johnson & Johnson Secures its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?A Silent Winner: Texas Instruments Anchors the AI SupercycleDelta's Guidance Cut Could Spell Trouble for the Airline Industry5 Retail Picks to Watch as the Holiday Shopping Season Nears Upcoming Earnings Bank of America (10/14/2026)BlackRock (10/14/2026)Morgan Stanley (10/14/2026)Progressive (10/14/2026)Fastenal (10/14/2026)ASML (10/14/2026)Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
